{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T11:24:35Z","timestamp":1787397875819,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04315-7","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T17:57:27Z","timestamp":1775498247000},"page":"4150-4159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Moderate hypofractionation: long-term toxicity results of prostate bed radiotherapy (FRAME-PROSTATE)"],"prefix":"10.1007","volume":"28","author":[{"given":"Federico","family":"Camilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Caini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Doccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Saldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Festa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Giulia","family":"Becchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Gravante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Bellavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Aristei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4380-6947","authenticated-orcid":false,"given":"Gianluca","family":"Ingrosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"4315_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","volume":"75","author":"D Tilki","year":"2019","unstructured":"Tilki D, Preisser F, Graefen M, et al. External validation of the European Association of Urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort. Eur Urol. 2019;75:896\u2013900.","journal-title":"Eur Urol"},{"key":"4315_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","volume":"396","author":"CC Parker","year":"2020","unstructured":"Parker CC, Clarke NW, Cook AD, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396:1413\u201321.","journal-title":"Lancet"},{"key":"4315_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","volume":"21","author":"A Kneebone","year":"2020","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020;21:1331\u201340.","journal-title":"Lancet Oncol"},{"key":"4315_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos P, Chabaud S, Latorzeff I, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21:1341\u201352.","journal-title":"Lancet Oncol"},{"key":"4315_CR5","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","volume":"396","author":"CL Vale","year":"2020","unstructured":"Vale CL, Fisher D, Kneebone A, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020;396:1422\u201331.","journal-title":"Lancet"},{"key":"4315_CR6","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack A, Karrison TG, Balogh AG, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399:1886\u2013901.","journal-title":"Lancet"},{"key":"4315_CR7","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","volume":"20","author":"C Carrie","year":"2019","unstructured":"Carrie C, Magn\u00e9 N, Burban-Provost P, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20:1740\u20139.","journal-title":"Lancet Oncol"},{"key":"4315_CR8","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton CN, Lukka H, Gu CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35:1884\u201390.","journal-title":"J Clin Oncol"},{"key":"4315_CR9","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17:1047\u201360.","journal-title":"Lancet Oncol"},{"key":"4315_CR10","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, et al. Randomized Phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34:2325\u201332.","journal-title":"J Clin Oncol"},{"key":"4315_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11547-024-01782-2","volume":"129","author":"G Ingrosso","year":"2024","unstructured":"Ingrosso G, Ponti E, Francolini G, et al. Image-guided moderately hypofractionated radiotherapy for localized prostate cancer: a multicentric retrospective study (IPOPROMISE). Radiol Med. 2024;129:643\u201352.","journal-title":"Radiol Med"},{"key":"4315_CR12","first-page":"1221","volume":"38","author":"G Siepe","year":"2018","unstructured":"Siepe G, Buwenge M, Nguyen NP, et al. Postoperative hypofractionated radiation therapy in prostate carcinoma: a systematic review. Anticancer Res. 2018;38:1221\u201330.","journal-title":"Anticancer Res"},{"key":"4315_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ctrv.2017.11.004","volume":"62","author":"C Picardi","year":"2018","unstructured":"Picardi C, Perret I, Miralbell R, Zilli T. Hypofractionated radiotherapy for prostate cancer in the postoperative setting: what is the evidence so far? Cancer Treat Rev. 2018;62:91\u20136.","journal-title":"Cancer Treat Rev"},{"key":"4315_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.radonc.2007.07.017","volume":"84","author":"P Poortmans","year":"2007","unstructured":"Poortmans P, Bossi A, Vandeputte K, et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol. 2007;84:121\u20137.","journal-title":"Radiother Oncol"},{"key":"4315_CR15","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.ijrobp.2015.03.021","volume":"92","author":"VA Harris","year":"2015","unstructured":"Harris VA, Staffurth J, Naismith O, et al. Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92:874\u201383.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4315_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijrobp.2018.08.016","volume":"103","author":"S Saldi","year":"2019","unstructured":"Saldi S, Bellavita R, Lancellotta V, et al. Acute toxicity profiles of hypofractionated adjuvant and salvage radiation therapy after radical prostatectomy: results of a prospective study. Int J Radiat Oncol Biol Phys. 2019;103:105\u201311.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4315_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11547-022-01465-w","volume":"127","author":"G Francolini","year":"2022","unstructured":"Francolini G, Jereczek-Fossa BA, Di Cataldo V, et al. Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis. Radiol Med. 2022;127:449\u201357.","journal-title":"Radiol Med"},{"key":"4315_CR18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ijrobp.2020.01.008","volume":"107","author":"S Chin","year":"2020","unstructured":"Chin S, Fatimilehin A, Walshaw R, et al. Ten-year outcomes of moderately hypofractionated salvage postprostatectomy radiation therapy and external validation of a contemporary multivariable nomogram for biochemical failure. Int J Radiat Oncol Biol Phys. 2020;107:288\u201396.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4315_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102102","volume":"22","author":"A Castelluccia","year":"2024","unstructured":"Castelluccia A, Tramacere F, Colciago RR, et al. 10-yr results of moderately hypofractionated postoperative radiotherapy for prostate cancer focused on treatment related toxicity. Clin Genitourin Cancer. 2024;22:102102.","journal-title":"Clin Genitourin Cancer"},{"key":"4315_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00066-020-01691-z","volume":"197","author":"C Franzese","year":"2021","unstructured":"Franzese C, Badalamenti M, Baldaccini D, et al. Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity. Strahlenther Onkol. 2021;197:133\u201340.","journal-title":"Strahlenther Onkol"},{"key":"4315_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s10147-017-1174-2","volume":"23","author":"K Nakamura","year":"2018","unstructured":"Nakamura K, Mizowaki T, Inokuchi H, et al. Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance. Int J Clin Oncol. 2018;23:158\u201364.","journal-title":"Int J Clin Oncol"},{"key":"4315_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00432-021-03816-y","volume":"148","author":"G Ferrera","year":"2022","unstructured":"Ferrera G, D\u2019Alessandro S, Cuccia F, et al. Post-operative hypofractionated radiotherapy for prostate cancer: a mono-institutional analysis of toxicity and clinical outcomes. J Cancer Res Clin Oncol. 2022;148:89\u201395.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4315_CR23","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.2147\/CMAR.S182016","volume":"10","author":"F Cuccia","year":"2018","unstructured":"Cuccia F, Mortellaro G, Serretta V, et al. Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes. Cancer Manag Res. 2018;10:5053\u201360.","journal-title":"Cancer Manag Res"},{"key":"4315_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ijrobp.2009.07.1742","volume":"78","author":"BA Jereczek-Fossa","year":"2010","unstructured":"Jereczek-Fossa BA, Zerini D, Fodor C, et al. Correlation between acute and late toxicity in 973 prostate cancer patients treated with three-dimensional conformal external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78:26\u201334.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4315_CR25","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.eururo.2014.06.012","volume":"66","author":"C Cozzarini","year":"2014","unstructured":"Cozzarini C, Fiorino C, Deantoni C, et al. Higher-than-expected severe (Grade 3\u20134) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur Urol. 2014;66:1024\u201330.","journal-title":"Eur Urol"},{"key":"4315_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.eururo.2021.05.033","volume":"80","author":"P Ghadjar","year":"2021","unstructured":"Ghadjar P, Hayoz S, Bernhard J, et al. Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09\/10 randomized phase 3 trial. Eur Urol. 2021;80:306\u201315.","journal-title":"Eur Urol"},{"key":"4315_CR27","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.annonc.2025.01.017","volume":"36","author":"A Dal Pra","year":"2025","unstructured":"Dal Pra A, Ghadjar P, Ryu HM, et al. Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG\/RTOG 0126 and SAKK 09\/10 trials. Ann Oncol. 2025;36:572\u201382.","journal-title":"Ann Oncol"},{"key":"4315_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.111040","volume":"211","author":"C Schr\u00f6der","year":"2025","unstructured":"Schr\u00f6der C, Zwahlen DR, Sch\u00e4r S, et al. Long-term urinary continence and influencing factors after salvage radiotherapy: results of the SAKK 09\/10 dose escalation trial. Radiother Oncol. 2025;211:111040.","journal-title":"Radiother Oncol"},{"key":"4315_CR29","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1007\/s00330-024-11134-3","volume":"35","author":"A Lancia","year":"2025","unstructured":"Lancia A, Ingrosso G, Zilli T. Prostate MRI: bridging radiology and radiation oncology for precision radiation therapy. Eur Radiol. 2025;35:2418\u20139.","journal-title":"Eur Radiol"},{"key":"4315_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.radonc.2022.08.001","volume":"175","author":"C Cozzarini","year":"2022","unstructured":"Cozzarini C, Olivieri M, Magli A, et al. Accurate prediction of long-term risk of biochemical failure after salvage radiotherapy including the impact of pelvic node irradiation. Radiother Oncol. 2022;175:26\u201332.","journal-title":"Radiother Oncol"},{"key":"4315_CR31","doi-asserted-by":"publisher","first-page":"252.e1","DOI":"10.1016\/j.urolonc.2022.12.001","volume":"41","author":"G Ozyigit","year":"2023","unstructured":"Ozyigit G, Onal C, Beduk Esen CS, et al. Treatment outcomes of postoperative ultra-hypofractionated stereotactic body radiotherapy in prostate cancer. Urol Oncol. 2023;41:252.e1-252.e8.","journal-title":"Urol Oncol"},{"key":"4315_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.111072","volume":"211","author":"F Ferrario","year":"2025","unstructured":"Ferrario F, Franzese C, Vukcaj S, et al. Predictors of toxicities and oncological outcomes following postoperative ablative radiotherapy (POPART) for biochemical recurrence. Radiother Oncol. 2025;211:111072.","journal-title":"Radiother Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04315-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04315-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04315-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T11:04:43Z","timestamp":1787396683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04315-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4315"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04315-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Long-terM toxicity rEsults of PROSTATE bed radiotherapy (FRAME-PROSTATE)] was approved by the Ethical Committee\u2014Regione Umbria (Approval N. CE1056\/24, 24\/07\/2024).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare that there are no competing financial interests concerning the work described.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided informed consent for this analysis. The protocol [moderate hypoFRActionation: long-terM toxicityrEsults of PROSTATE bed radiotherapy (FRAME-PROSTATE)] was approved by the Ethical Committee - RegioneUmbria (Approval N. CE1056\/24, 24\/07\/2024).","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}